GrayBug LLC
Delivering drugs to eye compartments, slowly
This article was originally published in Start Up
Executive Summary
Nearly 12 million intravitreal injections for ophthalmic disease were admistered to patients eyes in 2012, and the figure is a testament to the acceptability of the delivery method whose very concept once inspired gasps and doubts; still, meaningful improvements are almost certain to be welcome and reimbursed in the marketplace. GrayBug LLC is betting it can enhance the outcome of drugs injected into the eye by prolonging their release with a polymer-based delivery system that the firm expects to eventually be formulated as nanoparticles – the goal is to extend intervals between ocular medicine dosing to three months or longer, perhaps as long as six months, with reduced inflammatory effects.
You may also be interested in...
Finance Watch: Chinook Debuts With $65m For Precision Kidney Disease Medicines
Private Company Edition: The start-up intends to take multiple drug candidates into the clinic by 2021. Also, Graybug Vision raises an $80m series B and Finch closes a $53m series C.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.